Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00006103
Status:
COMPLETED
Last Update Posted:
2016-07-06
First Post:
2000-08-03
Brief Title:
Combination Chemotherapy in Treating Patients With Colorectal Cancer
Sponsor:
Alliance for Clinical Trials in Oncology
Organization:
Alliance for Clinical Trials in Oncology
Study Overview
Official Title:
Interracial Study of CPT-11 Irinotecan Pharmacokinetics in 5-Fluorouracil Refractory Colorectal Cancer A Population PharmacokineticPharmacodynamic Study of CPT-11
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die It is not yet known if the effectiveness of irinotecan combined with fluorouracil in treating colorectal cancer varies depending on the patients racial background
PURPOSE Phase III trial to study the effectiveness of irinotecan combined with fluorouracil in treating patients from different racial backgrounds who have colorectal cancer that is advanced recurrent metastatic or has not responded to treatment with fluorouracil
PURPOSE Phase III trial to study the effectiveness of irinotecan combined with fluorouracil in treating patients from different racial backgrounds who have colorectal cancer that is advanced recurrent metastatic or has not responded to treatment with fluorouracil
Detailed Description:
OBJECTIVES
Determine the interracial differences in the pharmacokinetics of irinotecan in combination with fluorouracil in terms of SN-38 glucuronidation and biliary index and gastrointestinal GI toxicity in patients with metastatic locally advanced or recurrent colorectal cancer
Determine if there is a significant relationship between UGT1A1 genotype promoter andor coding region mutation and CYP3A4 promoter genotype vs GI toxicity bone marrow toxicity and pharmacokinetics of irinotecan in this patient population
OUTLINE Patients are stratified according to race Asian or Pacific Islander vs black vs Hispanic vs white
Patients receive irinotecan IV over 90 minutes leucovorin calcium IV and fluorouracil IV on days 1 8 15 and 22 Treatment repeats every 6 weeks for a total of 5 courses in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 1 year and then every 6 months thereafter
PROJECTED ACCRUAL A total of 400 patients 100 per stratum will be accrued for this study within 3 years
Determine the interracial differences in the pharmacokinetics of irinotecan in combination with fluorouracil in terms of SN-38 glucuronidation and biliary index and gastrointestinal GI toxicity in patients with metastatic locally advanced or recurrent colorectal cancer
Determine if there is a significant relationship between UGT1A1 genotype promoter andor coding region mutation and CYP3A4 promoter genotype vs GI toxicity bone marrow toxicity and pharmacokinetics of irinotecan in this patient population
OUTLINE Patients are stratified according to race Asian or Pacific Islander vs black vs Hispanic vs white
Patients receive irinotecan IV over 90 minutes leucovorin calcium IV and fluorouracil IV on days 1 8 15 and 22 Treatment repeats every 6 weeks for a total of 5 courses in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 1 year and then every 6 months thereafter
PROJECTED ACCRUAL A total of 400 patients 100 per stratum will be accrued for this study within 3 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000068113 | REGISTRY | NCI Physician Data Query | httpsreporternihgovquickSearchU10CA031946 |
| U10CA031946 | NIH | None | None |
| CLB-9864 | None | None | None |
| E-C9864 | None | None | None |